Cargando…
Impact of hypertension on various markers of subclinical atherosclerosis in early type 2 diabetes
BACKGROUND: Presence of Diabetes Mellitus increases the risk of subclinical atherosclerosis. In this study was aimed to determine the influence of hypertension (HTN) on surrogate markers of atherosclerosis in a population of patients with early type 2 diabetes. METHODS: 125 diabetic subjects drawn f...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3933380/ https://www.ncbi.nlm.nih.gov/pubmed/24476202 http://dx.doi.org/10.1186/2251-6581-13-24 |
_version_ | 1782304924161277952 |
---|---|
author | Alatab, Sudabeh Fakhrzadeh, Hossein Sharifi, Farshad Mostashfi, Ali Mirarefin, Mojde Badamchizadeh, Zohreh Tagalizadehkhoob, Yaser |
author_facet | Alatab, Sudabeh Fakhrzadeh, Hossein Sharifi, Farshad Mostashfi, Ali Mirarefin, Mojde Badamchizadeh, Zohreh Tagalizadehkhoob, Yaser |
author_sort | Alatab, Sudabeh |
collection | PubMed |
description | BACKGROUND: Presence of Diabetes Mellitus increases the risk of subclinical atherosclerosis. In this study was aimed to determine the influence of hypertension (HTN) on surrogate markers of atherosclerosis in a population of patients with early type 2 diabetes. METHODS: 125 diabetic subjects drawn from Dr. Shariati outpatient’s clinic list and 153 non- diabetic subjects who were the relatives in law of diabetic participants were recruited. Participants with type 2 diabetes were free of clinical evidence of cardiovascular disease and renal involvement. Two groups of diabetic and control were further divided into two subgroups of hypertensive (known case of HTN or blood pressure ≥140/90 mmHg) and normotensive, and anthropometric characteristics, metabolic biomarkers as well as markers of subclinical atherosclerosis including Carotid intima media thickness (CIMT), flow mediated dilation (FMD) and Ankle Brachial Index (ABI) were measured. RESULTS: Diabetic group with a mean age of 49.9 ± 7.5 years had significantly higher CIMT (0.64 ± 0.14 vs 0.76 ± 0.19, p = 0.001) and lower FMD (16.5 ± 8.1 vs 13.3 ± 7.1, p = 0.003) and ABI (1.2 ± 0.1 vs 1.1 ± 0.1, p = 0.01) than control with mean age of 52.9 ± 10.1 years. 34% of control and 59.2% of diabetic were hypertensive. Fasting blood sugar, insulin levels and calculated insulin resistance index of HOMA IR. of hypertensive subjects were higher than normotensive subjects in both groups of diabetic and non-diabetic. Similar pattern was presented for measured inflammatory mediators of hs-CRP and IL-6. Among subclinical atherosclerosis markers, only CIMT was significantly different between hypertensive and normotensive subjects in both groups. In adjusted linear regression analysis, a constant significant association existed between age and CIMT, ABI and FMD in non-diabetic, while in diabetic, age only correlated with CIMT and not the other two markers. In multiple regression model, HTN was recognized as a risk factor for increasing CIMT (OR = 2.93, 95% CI = 1.03-8.33, p = 0.04) but not attenuating FMD or ABI. CONCLUSIONS: Since FMD and CIMT may measure a different stage of subclinical atherosclerosis in diabetic patients, influence of HTN on these markers might be different. |
format | Online Article Text |
id | pubmed-3933380 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-39333802014-02-25 Impact of hypertension on various markers of subclinical atherosclerosis in early type 2 diabetes Alatab, Sudabeh Fakhrzadeh, Hossein Sharifi, Farshad Mostashfi, Ali Mirarefin, Mojde Badamchizadeh, Zohreh Tagalizadehkhoob, Yaser J Diabetes Metab Disord Research Article BACKGROUND: Presence of Diabetes Mellitus increases the risk of subclinical atherosclerosis. In this study was aimed to determine the influence of hypertension (HTN) on surrogate markers of atherosclerosis in a population of patients with early type 2 diabetes. METHODS: 125 diabetic subjects drawn from Dr. Shariati outpatient’s clinic list and 153 non- diabetic subjects who were the relatives in law of diabetic participants were recruited. Participants with type 2 diabetes were free of clinical evidence of cardiovascular disease and renal involvement. Two groups of diabetic and control were further divided into two subgroups of hypertensive (known case of HTN or blood pressure ≥140/90 mmHg) and normotensive, and anthropometric characteristics, metabolic biomarkers as well as markers of subclinical atherosclerosis including Carotid intima media thickness (CIMT), flow mediated dilation (FMD) and Ankle Brachial Index (ABI) were measured. RESULTS: Diabetic group with a mean age of 49.9 ± 7.5 years had significantly higher CIMT (0.64 ± 0.14 vs 0.76 ± 0.19, p = 0.001) and lower FMD (16.5 ± 8.1 vs 13.3 ± 7.1, p = 0.003) and ABI (1.2 ± 0.1 vs 1.1 ± 0.1, p = 0.01) than control with mean age of 52.9 ± 10.1 years. 34% of control and 59.2% of diabetic were hypertensive. Fasting blood sugar, insulin levels and calculated insulin resistance index of HOMA IR. of hypertensive subjects were higher than normotensive subjects in both groups of diabetic and non-diabetic. Similar pattern was presented for measured inflammatory mediators of hs-CRP and IL-6. Among subclinical atherosclerosis markers, only CIMT was significantly different between hypertensive and normotensive subjects in both groups. In adjusted linear regression analysis, a constant significant association existed between age and CIMT, ABI and FMD in non-diabetic, while in diabetic, age only correlated with CIMT and not the other two markers. In multiple regression model, HTN was recognized as a risk factor for increasing CIMT (OR = 2.93, 95% CI = 1.03-8.33, p = 0.04) but not attenuating FMD or ABI. CONCLUSIONS: Since FMD and CIMT may measure a different stage of subclinical atherosclerosis in diabetic patients, influence of HTN on these markers might be different. BioMed Central 2014-01-29 /pmc/articles/PMC3933380/ /pubmed/24476202 http://dx.doi.org/10.1186/2251-6581-13-24 Text en Copyright © 2014 Alatab et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Alatab, Sudabeh Fakhrzadeh, Hossein Sharifi, Farshad Mostashfi, Ali Mirarefin, Mojde Badamchizadeh, Zohreh Tagalizadehkhoob, Yaser Impact of hypertension on various markers of subclinical atherosclerosis in early type 2 diabetes |
title | Impact of hypertension on various markers of subclinical atherosclerosis in early type 2 diabetes |
title_full | Impact of hypertension on various markers of subclinical atherosclerosis in early type 2 diabetes |
title_fullStr | Impact of hypertension on various markers of subclinical atherosclerosis in early type 2 diabetes |
title_full_unstemmed | Impact of hypertension on various markers of subclinical atherosclerosis in early type 2 diabetes |
title_short | Impact of hypertension on various markers of subclinical atherosclerosis in early type 2 diabetes |
title_sort | impact of hypertension on various markers of subclinical atherosclerosis in early type 2 diabetes |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3933380/ https://www.ncbi.nlm.nih.gov/pubmed/24476202 http://dx.doi.org/10.1186/2251-6581-13-24 |
work_keys_str_mv | AT alatabsudabeh impactofhypertensiononvariousmarkersofsubclinicalatherosclerosisinearlytype2diabetes AT fakhrzadehhossein impactofhypertensiononvariousmarkersofsubclinicalatherosclerosisinearlytype2diabetes AT sharififarshad impactofhypertensiononvariousmarkersofsubclinicalatherosclerosisinearlytype2diabetes AT mostashfiali impactofhypertensiononvariousmarkersofsubclinicalatherosclerosisinearlytype2diabetes AT mirarefinmojde impactofhypertensiononvariousmarkersofsubclinicalatherosclerosisinearlytype2diabetes AT badamchizadehzohreh impactofhypertensiononvariousmarkersofsubclinicalatherosclerosisinearlytype2diabetes AT tagalizadehkhoobyaser impactofhypertensiononvariousmarkersofsubclinicalatherosclerosisinearlytype2diabetes |